Skip to main content

Diabetes

  • White paper: Diabetes diagnoses doubles across pediatric population

    NEW YORK  — Private health insurance claim lines with a type 2 diabetes diagnosis more than doubled in the pediatric population (ages 0 to 22 years) from 2011 to 2015, increasing 109%, according to data from FAIR Health, a national, independent, nonprofit organization dedicated to bringing transparency to healthcare costs and health insurance information.

  • Sanofi announces U.S. availability of Soliqua 100/33
    PARIS — Sanofi on Wednesday announced the U.S. availability of its Soliqua 100/33  (insulin glargine 100 units/mL and lixisenatide 33 mcg/mL) injection pen. The drug, approved by the Food and Drug Administration in November, is indicated to treat adults with Type 2 diabetes that’s inadequately controlled on basal insulin or lixisenatide. 
     

  • FDA clears integration of OneTouch meter with WellDoc's diabetes management platform

    CHESTERBROOK, Pa. — LifeScan, part of the Johnson & Johnson Diabetes Care Companies, earlier this week announced the U.S. Food and Drug Administration has cleared the wireless integration of the OneTouch Verio Flex blood glucose monitoring system with WellDoc's clinically validated diabetes management platform, BlueStar, creating a unique digital health solution for people living with Type 2 diabetes.

  • Lilly, Boehringer Ingelheim launch Lantus follow-on Basaglar
    INDIANAPOLIS and RIDGEFIELD, Conn. — Eli Lilly and Co. and Boehringer Ingelheim Pharmaceuticals on Thursday announced the launch and availability of their Basaglar. The drug is a follow-on insulin to U-100 insulin glargine Lantus and is a long-acting insulin with an amino acid sequence identical to that of Lantus. 
     

  • FDA approves Synjardy XR from Lilly, Boehringer Ingelheim
    RIDGEFIELD, Conn. and INDIANAPOLIS — The Food and Drug Administration has approved Eli Lilly & Co.’s and Boehringer Ingelheim’s Synjardy XR (empagliflozin and metformin hydrochloride) extended-release tablets. The drug is indicated to improve blood sugar in adults with Type 2 diabetes when both empagliflozin and metformin can be taken. 
     

  • Lilly rolls out insulin discount program
    INDIANAPOLIS, Ind. —  Eli Lilly & Co. has outlined a new initiative, set to begin Jan. 1, 2017, that will offer access to Lilly insulin at discounted prices to patients via Blink Health’s mobile and web platforms through a partnership with Express Scripts. 
     

  • Apple disrupts diabetes management with subscription service

    NEW YORK — One Drop on Tuesday announced that it has received U.S. Food and Drug Administration 510(k) clearance and Conformité Européene (CE) mark approval for One Drop | Chrome, a blood glucose monitoring system that marries modern design with advanced medical and mobile technology.

  • Genteel alternate-site lancet device gains FDA clearance

    MIDLAND, Texas — Genteel on Tuesday announced clearance by the U.S. Food & Drug Administration for its “gentle” lancing device. Genteel is the only FDA-cleared standalone lancing device that performs ample blood draw from other body sites as well as fingers.

X
This ad will auto-close in 10 seconds